Biomaterial

United States 3D Printing Markets, Competition Forecast & Opportunities, 2028F: Significant Expansion Driven by Technological Innovations and Applications in Aerospace and Healthcare - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Chemicals, Plastics, Attention, Growth, Surgeon, Health, Science, Printing, Biomaterial, Partnership, Intellectual property, Anatomy, COVID-19, Quality control, Research, Boeing, 3D, NASA, Investment, Ecosystem, Safety, 3D Systems, SpaceX, Stratasys, HP, 3D printing

The "United States 3D Printing Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States 3D Printing Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.
  • The United States 3D printing market has emerged as a dynamic and transformative force in the global manufacturing landscape.
  • One of the primary drivers of the 3D printing market in the United States is the continuous innovation in 3D printing technologies.
  • American companies and research institutions have been at the forefront of developing cutting-edge 3D printing techniques, materials, and processes.

PLGA Market worth $321 Million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 27, 2024
PLGA, Tissue engineering, Mitsui Chemicals, Health, Biomaterial, Biomedical Research, Investment, Pollution, Therapy, Administration

PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.

Key Points: 
  • PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.
  • This manufacturing technique involves injecting molten PLGA resin into a mold cavity under high pressure, where it solidifies to form the desired shape.
  • "North America captures the largest share in the PLGA market during the forecast period, in terms of value."
  • The PLGA market in North America stands as a vibrant and evolving landscape within the realm of biodegradable polymers.

PLGA Market worth $321 Million by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 27, 2024
PLGA, Tissue engineering, Mitsui Chemicals, Health, Biomaterial, Biomedical Research, Investment, Pollution, Therapy, Administration

PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.

Key Points: 
  • PLGA, renowned for its biodegradability, biocompatibility, and tunable properties, lends itself exceptionally well to the injection molding process.
  • This manufacturing technique involves injecting molten PLGA resin into a mold cavity under high pressure, where it solidifies to form the desired shape.
  • "North America captures the largest share in the PLGA market during the forecast period, in terms of value."
  • The PLGA market in North America stands as a vibrant and evolving landscape within the realm of biodegradable polymers.

Medical Polymers Market Size to Grow USD 21320 Million by 2029 at a CAGR of 3.1% | Valuates Reports

Retrieved on: 
Wednesday, February 7, 2024
Polymer, Stent, Regenerative medicine, Conditional sentence, Biomaterial, Catheter, Ageing, Packaging and labeling, DSM, Polyethylene, PVC, Incidence, Tissue engineering, Biodegradable plastic, Polyvinyl chloride, Medical device, Diabetes, Administration, Risk, Cancer, Equipment, BASF

BANGALORE, India , Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).

Key Points: 
  • BANGALORE, India , Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).
  • The growing need for biocompatible materials in the healthcare industry is driving the expansion of the medical polymers market.
  • Biocompatible polymers, including polyethylene, polypropylene , and polyvinyl chloride (PVC) , find widespread application in drug delivery systems, implants, and medical devices.
  • https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-18T15867...
    The top companies in the worldwide market for medical polymers include BASF SE, Bayer, Celanese, DSM, Du Pont, and others.

Medical Polymers Market Size to Grow USD 21320 Million by 2029 at a CAGR of 3.1% | Valuates Reports

Retrieved on: 
Wednesday, February 7, 2024
Polymer, Stent, Regenerative medicine, Conditional sentence, Biomaterial, Catheter, Ageing, Packaging and labeling, DSM, Polyethylene, PVC, Incidence, Tissue engineering, Biodegradable plastic, Polyvinyl chloride, Medical device, Diabetes, Administration, Risk, Cancer, Equipment, BASF

BANGALORE, India, Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).

Key Points: 
  • BANGALORE, India, Feb. 7, 2024 /PRNewswire/ -- Medical Polymers Market is Segmented by Type (Medical Resins and Fibers, Medical Elastomers, Biodegradable Plastics), by Application (Medical Devices and Equipment, Medical Packaging).
  • The growing need for biocompatible materials in the healthcare industry is driving the expansion of the medical polymers market.
  • Biocompatible polymers, including polyethylene, polypropylene , and polyvinyl chloride (PVC) , find widespread application in drug delivery systems, implants, and medical devices.
  • https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-18T15867...
    The top companies in the worldwide market for medical polymers include BASF SE, Bayer, Celanese, DSM, Du Pont, and others.

3D Bio-Printing Industry to Surpass a Valuation of US$ 6.82 billion By 2034. Players to Capitalize on the Rising Demand for 3D Bio-printing during the Forecast Period

Retrieved on: 
Wednesday, January 24, 2024
Organ transplantation, Regenerative medicine, Patient, Research, Associate, Injury, Material, Tissue, 3D bioprinting, Risk, Quality of life, Investment, Tissue engineering, 3D, Printing, Transplant, Biomaterial, FMI, Elasticity, Growth, 3D printing

NEWARK, Del., Jan. 24, 2024 /PRNewswire/ -- The global 3D Bio-Printing Market is expected to grow at an exponential CAGR of 11.8% between 2024 and 2034, to reach US$ 2.24 billion in 2024 and US$ 6.82 billion by 2034. The desire for customized medicine, growing investments in bio printing technology, partnerships between biotech firms, healthcare providers, and research institutes, as well as advancements in tissue engineering and regenerative medicine, are driving the growth of the worldwide 3D bio-printing demand.

Key Points: 
  • This development has significantly enhanced the accuracy and functionality of 3D printed structures, making them more suitable for biomedical applications.
  • The growing demand for 3D bio-printing is a significant trend driven by the need for personalized medicine .
  • Collaborations with academic institutes and healthcare organizations promote a multidisciplinary approach, hastening the translation of 3D bio-printing into therapeutic applications.
  • Market players are always exploring new materials to enhance the biocompatibility and structural integrity of printed tissues, such as bio-inks and biomimetic compounds.

3D Bio-Printing Industry to Surpass a Valuation of US$ 6.82 billion By 2034. Players to Capitalize on the Rising Demand for 3D Bio-printing during the Forecast Period

Retrieved on: 
Wednesday, January 24, 2024
Organ transplantation, Regenerative medicine, Patient, Research, Associate, Injury, Material, Tissue, 3D bioprinting, Risk, Quality of life, Investment, Tissue engineering, 3D, Printing, Transplant, Biomaterial, FMI, Elasticity, Growth, 3D printing

NEWARK, Del., Jan. 24, 2024 /PRNewswire/ -- The global 3D Bio-Printing Market is expected to grow at an exponential CAGR of 11.8% between 2024 and 2034, to reach US$ 2.24 billion in 2024 and US$ 6.82 billion by 2034. The desire for customized medicine, growing investments in bio printing technology, partnerships between biotech firms, healthcare providers, and research institutes, as well as advancements in tissue engineering and regenerative medicine, are driving the growth of the worldwide 3D bio-printing demand.

Key Points: 
  • This development has significantly enhanced the accuracy and functionality of 3D printed structures, making them more suitable for biomedical applications.
  • The growing demand for 3D bio-printing is a significant trend driven by the need for personalized medicine .
  • Collaborations with academic institutes and healthcare organizations promote a multidisciplinary approach, hastening the translation of 3D bio-printing into therapeutic applications.
  • Market players are always exploring new materials to enhance the biocompatibility and structural integrity of printed tissues, such as bio-inks and biomimetic compounds.

Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders

Retrieved on: 
Wednesday, December 13, 2023
Research, Technology, Diabetes, Software, Stem Cells, Biotechnology, Hardware, Pharmaceutical, Health, Science, Patient, College of Engineering (KNUST), Doctor of Philosophy, Y Combinator, Type 1 diabetes, Biomaterial, Cell encapsulation, Nanotechnology, Khosla Ventures, Cell, Pharmaceutical industry, Medical device, T1D

Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.

Key Points: 
  • Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
  • Preclinical data with its first candidate, using ENC-201 in T1D, reported no fibrosis, or immune response, while maintaining cell viability and function.
  • “This new financing led by Khosla Ventures, enables us to advance development of our Cell Encapsulation platform, which aims to provide years of therapeutic benefit with a single implant.
  • The technology can be used in a variety of different indications, beginning with chronic endocrine disorders,” said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin.

Orthopedic 3D printed devices market size to grow by USD 1.35 billion from 2023 to 2028 | North America to account for 40% of market growth- Technavio

Retrieved on: 
Thursday, December 14, 2023
EOS, Plastic, ROW, Renishaw plc, SLM Solutions Group AG, Research, 3D Systems, USD, Zimmer Biomet, Medtronic, Biomaterial, Instrument, Geography, Growth, 3D, Smith, Device, Medical device, Retail, 3D printing

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The orthopedic 3D printed devices market size is expected to grow by USD 1.35 billion from 2023 to 2028.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- The orthopedic 3D printed devices market size is expected to grow by USD 1.35 billion from 2023 to 2028.
  • Orthopedic 3D Printed Devices Market: Segmentation Analysis
    The orthopedic implants segment is estimated to witness significant growth during the forecast period.
  • Detailed information on factors that will drive the growth of the orthopedic 3D printed devices market between 2023 and 2028.
  • Growth of the market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of orthopedic 3D printed devices market companies.

Stora Enso's fourth quarter 2023 impairment test results

Retrieved on: 
Tuesday, December 12, 2023
Biomaterial, STE, Depreciation, EUR, ADR (treaty), Nordic

HELSINKI, Dec. 12, 2023 /PRNewswire/ -- Stora Enso will record non-cash impairments of approximately EUR 514 million in its IFRS operating result in the fourth quarter of 2023. The impairments will be reported as an item affecting comparability (IAC). Including the estimated positive tax effect of EUR 65 million, the net result impact will be approximately EUR 449 million negative.

Key Points: 
  • The impairments are mainly a consequence of Stora Enso's predictions of a weaker outlook compared to previous estimates.
  • As a result of the impairment booking, the annual depreciation will decrease by approximately EUR 40 million going forward.
  • The impairments do not impact Stora Enso's full-year 2023 guidance.
  • Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R).